Unknown PHASE1 INTERVENTIONAL 3-arm NCT03730311

Phase Ib Study of Safety, Tolerability and Pharmacokinetics of Elpida Once Weekly in Healthy Volunteers

Phase Ib, Single-Centre, Placebo-Controlled Randomised Study of Safety, Tolerability and Pharmacokinetics of Elpida in Healthy HIV-Uninfected Volunteers

Sponsor: Viriom

Conditions HIV Infections

Interventions Elpida placebo

Updated 6 times since 2018 Last updated: May 16, 2019 Started: May 31, 2019 Primary completion: Nov 30, 2019 Completion: Dec 31, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates HIV Infections and is currently ongoing. Viriom leads this study, which shows 6 recorded versions since 2019 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE1
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1

Status: Unknown Status → Unknown
Oct 2021 — Jul 2024 [monthly]

Unknown Status PHASE1

Status: Not Yet Recruiting → Unknown Status
Jan 2021 — Oct 2021 [monthly]

Not Yet Recruiting PHASE1
Jun 2019 — Jan 2021 [monthly]

Not Yet Recruiting PHASE1

▶ Show 1 earlier version

Dec 2018 — Jun 2019 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Viriom

Data source: Viriom

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bangkok, Thailand